Wiese MD - Search Results

1

Ant venom immunotherapy: a double-blind, placebo-controlled, crossover trial.

Brown SG, Wiese MD, Blackman KE, Heddle RJ. Brown SG, et al. Among authors: wiese md. Lancet. 2003 Mar 22;361(9362):1001-6. doi: 10.1016/S0140-6736(03)12827-9. Lancet. 2003. PMID: 12660058 Clinical Trial.

2

Immediate-type hypersensitivity drug reactions.

Stone SF, Phillips EJ, Wiese MD, Heddle RJ, Brown SG. Stone SF, et al. Among authors: wiese md. Br J Clin Pharmacol. 2014 Jul;78(1):1-13. doi: 10.1111/bcp.12297. Br J Clin Pharmacol. 2014. PMID: 24286446 Free PMC article. Review.

3

Pharmaceutical and preclinical evaluation of Advax adjuvant as a dose-sparing strategy for ant venom immunotherapy.

Wanandy T, Honda-Okubo Y, Davies NW, Rose HE, Heddle RJ, Brown SGA, Woodman RJ, Petrovsky N, Wiese MD. Wanandy T, et al. Among authors: wiese md. J Pharm Biomed Anal. 2019 Aug 5;172:1-8. doi: 10.1016/j.jpba.2019.04.017. Epub 2019 Apr 9. J Pharm Biomed Anal. 2019. PMID: 31009889 Free PMC article.

4

Myrmecia pilosula (Jack Jumper) ant venom: identification of allergens and revised nomenclature.

Wiese MD, Brown SG, Chataway TK, Davies NW, Milne RW, Aulfrey SJ, Heddle RJ. Wiese MD, et al. Allergy. 2007 Apr;62(4):437-43. doi: 10.1111/j.1398-9995.2007.01320.x. Allergy. 2007. PMID: 17362256

5

Factors influencing the quality of Myrmecia pilosula (Jack Jumper) ant venom for use in in vitro and in vivo diagnoses of allergen sensitization and in allergen immunotherapy.

Wanandy T, Dwyer HE, McLean L, Davies NW, Nichols D, Gueven N, Brown SGA, Wiese MD. Wanandy T, et al. Among authors: wiese md. Clin Exp Allergy. 2017 Nov;47(11):1478-1490. doi: 10.1111/cea.12987. Epub 2017 Aug 31. Clin Exp Allergy. 2017. PMID: 28756642

6

Using time-resolved fluorescence to measure serum venom-specific IgE and IgG.

van Eeden PE, Wiese MD, Aulfrey S, Hales BJ, Stone SF, Brown SG. van Eeden PE, et al. Among authors: wiese md. PLoS One. 2011 Jan 31;6(1):e16741. doi: 10.1371/journal.pone.0016741. PLoS One. 2011. PMID: 21304970 Free PMC article.

7

Causes of ant sting anaphylaxis in Australia: the Australian Ant Venom Allergy Study.

Brown SG, van Eeden P, Wiese MD, Mullins RJ, Solley GO, Puy R, Taylor RW, Heddle RJ. Brown SG, et al. Among authors: wiese md. Med J Aust. 2011 Jul 18;195(2):69-73. doi: 10.5694/j.1326-5377.2011.tb03209.x. Med J Aust. 2011. PMID: 21770873

8

Ultrarush versus semirush initiation of insect venom immunotherapy: a randomized controlled trial.

Brown SG, Wiese MD, van Eeden P, Stone SF, Chuter CL, Gunner J, Wanandy T, Phillips M, Heddle RJ. Brown SG, et al. Among authors: wiese md. J Allergy Clin Immunol. 2012 Jul;130(1):162-8. doi: 10.1016/j.jaci.2012.02.022. Epub 2012 Mar 27. J Allergy Clin Immunol. 2012. PMID: 22460067 Clinical Trial.

9

Myrmecia pilosula (Jack Jumper) ant venom: validation of a procedure to standardise an allergy vaccine.

Wiese MD, Milne RW, Davies NW, Chataway TK, Brown SG, Heddle RJ. Wiese MD, et al. J Pharm Biomed Anal. 2008 Jan 7;46(1):58-65. doi: 10.1016/j.jpba.2007.08.028. Epub 2007 Sep 7. J Pharm Biomed Anal. 2008. PMID: 17933477

10

Proteomic analysis of Myrmecia pilosula (jack jumper) ant venom.

Wiese MD, Chataway TK, Davies NW, Milne RW, Brown SG, Gai WP, Heddle RJ. Wiese MD, et al. Toxicon. 2006 Feb;47(2):208-17. doi: 10.1016/j.toxicon.2005.10.018. Epub 2005 Dec 27. Toxicon. 2006. PMID: 16376960

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results